RELAY试验：厄洛替尼+ Ramucirumab或安慰剂治疗初治EGFR突变转移性NSCLC的最终总体生存率

文章预览

SCI 11 December 2024 RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC (Journal of Thoracic Oncology, IF: 21.0) Kazuhiko Nakagawa, MD, PhD, Edward B. Garon, MD, MS, Takashi Seto, MD, PhD, Makoto Nishio, MD, PhD, Santiago Ponce Aix, MD, Luis Paz-Ares, MD, PhD, Chao-Hua Chiu, MD, Keunchil Park, MD, PhD, Silvia Novello, MD, PhD, Ernest Nadal, MD, PhD, Kazumi Nishino, MD, PhD, Kiyotaka Yoh, MD, Jin-Yuan Shih, MD, PhD, Jeannie YK. Chik, MBBS, Denis Moro-Sibilot, MD, PhD, Tarun Puri, MD, Sunoj Chacko Varughese, Bente Frimodt-Moller, MSc, Carla Visseren-Grul, MD, Martin Reck, MD, PhD CORRESPONDENCE TO: nakagawa@med.kindai.ac.jp Background 背景 RELAY, a global double-blind, placebo-controlled Phase 3 study (NCT02411448) demonstrated statistically significant improvement in progression-free survival (PFS; primary endpoint) for ramucirumab (RAM)+erlotinib (ERL) in patients with untreated EGFR-mutated metastatic NSCLC: HR 0.59 (95% ………………………………